# OnCo record embraca (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/embraca/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "embraca", "NCT01945775" ;
  schema:name "EMBRACA"@en ;
  schema:description "EMBRACA showed that the PARP inhibitor talazoparib delays progression by about three months compared with chemotherapy in women with an inherited BRCA mutation and advanced breast cancer, with better quality of life but no gain in overall survival."@en ;
  schema:url <https://onco.cc/trials/embraca/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01945775>, <https://doi.org/10.1056/NEJMoa1802905> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/tnbc-metastatic/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/eribulin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/vinorelbine/> ;
  onco:terms <https://onco.cc/terms/gbrca-mutation/> ;
  onco:people <https://onco.cc/people/jennifer-litton/> .